LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Search

BioCryst Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

8.28 -0.24

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.27

Max

8.46

Pagrindiniai rodikliai

By Trading Economics

Pajamos

5.1M

5.1M

Pardavimai

18M

163M

Pelno marža

3.113

Darbuotojai

580

EBITDA

-84M

-62M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+110.59% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-88M

1.7B

Ankstesnė atidarymo kaina

8.52

Ankstesnė uždarymo kaina

8.28

Naujienos nuotaikos

By Acuity

32%

68%

94 / 371 reitingas Healthcare

BioCryst Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-02 23:07; UTC

Įsigijimai, susijungimai, perėmimai

Broadwood Partners Plans to Vote Against Staar Sale to Alcon

2025-09-02 22:10; UTC

Pagrindinės rinkos jėgos

Bruker Shares Fall on Convertible Share Offering Aimed at Debt Repayment

2025-09-02 21:47; UTC

Uždarbis

Alimentation Couche-Tard Logs Lower Profit, Revenue in 1Q

2025-09-02 16:52; UTC

Pagrindinės rinkos jėgos

CleanCore Solutions Shares Drop After $175 Million Private Investment

2025-09-02 22:47; UTC

Rinkos pokalbiai

Google, Apple Can Grow AI Deal With Lawsuit Resolved -- Market Talk

2025-09-02 21:40; UTC

Įsigijimai, susijungimai, perėmimai

Investors Have to Be Ready for State Capitalism. What Areas to Watch. -- Barrons.com

2025-09-02 21:07; UTC

Uždarbis

Couche-Tard 1Q U.S. Same-Store Merchandise Revenue Up 0.4% >ATD.T

2025-09-02 21:07; UTC

Uždarbis

Couche-Tard 1Q Canada Same-Store Merchandise Revenue Up 4.1% >ATD.T

2025-09-02 21:05; UTC

Uždarbis

Couche-Tard 1Q Rev $17.35B >ATD.T

2025-09-02 21:05; UTC

Uždarbis

Couche-Tard 1Q Adj EPS 78c >ATD.T

2025-09-02 21:05; UTC

Uždarbis

Couche-Tard 1Q EPS 82c >ATD.T

2025-09-02 21:05; UTC

Uždarbis

Couche-Tard 1Q Net $782.5M >ATD.T

2025-09-02 21:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2025-09-02 20:53; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Knight-Swift Transportation Endorses Union Pacific, Norfolk Southern Merger -- Market Talk

2025-09-02 20:51; UTC

Įsigijimai, susijungimai, perėmimai

Buffett Dislikes Breakup of Kraft Heinz. It's Been One of His Worst Investments. -- Barrons.com

2025-09-02 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-02 20:27; UTC

Uždarbis

NIO Stock Rises After Second-Quarter Loss Narrows -- Barrons.com

2025-09-02 20:24; UTC

Įsigijimai, susijungimai, perėmimai

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

2025-09-02 20:18; UTC

Įsigijimai, susijungimai, perėmimai

Procter & Gamble Does Not Endorse Tutanota's Unsolicited Mini-Tender Offer >PG

2025-09-02 20:17; UTC

Įsigijimai, susijungimai, perėmimai

Procter & Gamble: Tutanota Says It Expects to Extend Offer for Successive Periods of Up to 180 Days Until Market Price Exceeds Offer Price >PG

2025-09-02 20:16; UTC

Įsigijimai, susijungimai, perėmimai

Procter & Gamble: 'Shareholders Who Tender Their Shrs in the Offer Will Receive a Below-Market Price' >PG

2025-09-02 20:16; UTC

Įsigijimai, susijungimai, perėmimai

Procter & Gamble: Offer by Tutanota Is to Purchase Up to 500,000 Shrs at $128 Each

2025-09-02 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Procter & Gamble Has Been Notified of Unsolicited Mini-Tender Offer by Tutanota >PG

2025-09-02 19:55; UTC

Uždarbis

GM Had a Record Month of EV Sales. A 'Collapse' Is Coming. -- Barrons.com

2025-09-02 19:50; UTC

Įsigijimai, susijungimai, perėmimai

Food Giants Are Struggling. Could Mergers, Spinoffs, and Activist Stakes Help? -- Barrons.com

2025-09-02 19:09; UTC

Rinkos pokalbiai

Oil Futures Gain on Geopolitical Premium -- Market Talk

2025-09-02 19:00; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Recover $3 Level -- Market Talk

2025-09-02 18:12; UTC

Rinkos pokalbiai

Gold Pushes To New Record -- Market Talk

2025-09-02 17:04; UTC

Rinkos pokalbiai

Philip Morris Riding Smoke-Free Products to Higher Margins -- Market Talk

2025-09-02 16:57; UTC

Įsigijimai, susijungimai, perėmimai

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

BioCryst Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

110.59% į viršų

12 mėnesių prognozė

Vidutinis 17.5 USD  110.59%

Aukščiausias 30 USD

Žemiausias 12 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines BioCryst Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

6

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

94 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.